Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15

J. K.V. Willson, Daniel Albert, M. Diener-West, L. McCaffrey, C. S. Mo, R. E. Scully, N. Robinson, M. Zimbric

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Background: A systematic review and assessment of disease-related mortality as part of standardized prospective patient follow-up and evaluation within a multicenter clinical trial have been lacking in previous studies of choroidal melanoma. Objective: To describe disease status at death in patients with large choroidal melanoma treated and followed up in the Collaborative Ocular Melanoma Study (COMS). Design: Analysis of reviews of patient status at death performed by the COMS Mortality Coding Committee using available clinical and histopathologic information. Setting and Patients: Reviews of deaths as of July 31, 1997, the cutoff date for reporting initial mortality findings. Interventions: Patients were treated by either enucleation preceded by external beam radiotherapy or enucleation only. Main Outcome Measures: Disease status at the time of death and certainty associated with the coding of disease status, sites of metastasis, and availability of autopsy. Results: Of 1003 patients enrolled in the trial, 457 had died; the estimated median survival from time of enrollment was 7.4 years. Disease status at time of death had been reviewed for 435 deaths (95%). The autopsy rate was 6%. A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sties were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis. The likelihood of 3 or more sites increased more than 4-fold when autopsy results were available. Conclusions: Detailed mortality coding following a standard protocol provides the most accurate reporting to date of disease-related mortality in patients with choroidal melanoma and also identifies difficulties. Guidelines for the evaluation of future patients in clinical studies of choroidal melanoma are suggested.

Original languageEnglish (US)
Pages (from-to)670-676
Number of pages7
JournalArchives of ophthalmology
Volume119
Issue number5
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Melanoma
Mortality
Neoplasm Metastasis
Autopsy
Hordeolum
Multicenter Studies
Radiotherapy
Outcome Assessment (Health Care)
Clinical Trials
Guidelines
Bone and Bones
Lung
Survival
Liver

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15. / Willson, J. K.V.; Albert, Daniel; Diener-West, M.; McCaffrey, L.; Mo, C. S.; Scully, R. E.; Robinson, N.; Zimbric, M.

In: Archives of ophthalmology, Vol. 119, No. 5, 01.01.2001, p. 670-676.

Research output: Contribution to journalArticle

Willson, J. K.V. ; Albert, Daniel ; Diener-West, M. ; McCaffrey, L. ; Mo, C. S. ; Scully, R. E. ; Robinson, N. ; Zimbric, M. / Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15. In: Archives of ophthalmology. 2001 ; Vol. 119, No. 5. pp. 670-676.
@article{0648443a829146a19b8d3b15c2e7d9be,
title = "Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15",
abstract = "Background: A systematic review and assessment of disease-related mortality as part of standardized prospective patient follow-up and evaluation within a multicenter clinical trial have been lacking in previous studies of choroidal melanoma. Objective: To describe disease status at death in patients with large choroidal melanoma treated and followed up in the Collaborative Ocular Melanoma Study (COMS). Design: Analysis of reviews of patient status at death performed by the COMS Mortality Coding Committee using available clinical and histopathologic information. Setting and Patients: Reviews of deaths as of July 31, 1997, the cutoff date for reporting initial mortality findings. Interventions: Patients were treated by either enucleation preceded by external beam radiotherapy or enucleation only. Main Outcome Measures: Disease status at the time of death and certainty associated with the coding of disease status, sites of metastasis, and availability of autopsy. Results: Of 1003 patients enrolled in the trial, 457 had died; the estimated median survival from time of enrollment was 7.4 years. Disease status at time of death had been reviewed for 435 deaths (95{\%}). The autopsy rate was 6{\%}. A total of 269 patients (62{\%}) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21{\%}) on the basis of imaging and tests but without tissue confirmation. The common sties were liver (93{\%}), lung (24{\%}), and bone (16{\%}); multiple sites were identified in 87{\%} of patients with metastasis. The likelihood of 3 or more sites increased more than 4-fold when autopsy results were available. Conclusions: Detailed mortality coding following a standard protocol provides the most accurate reporting to date of disease-related mortality in patients with choroidal melanoma and also identifies difficulties. Guidelines for the evaluation of future patients in clinical studies of choroidal melanoma are suggested.",
author = "Willson, {J. K.V.} and Daniel Albert and M. Diener-West and L. McCaffrey and Mo, {C. S.} and Scully, {R. E.} and N. Robinson and M. Zimbric",
year = "2001",
month = "1",
day = "1",
doi = "10.1001/archopht.119.5.670",
language = "English (US)",
volume = "119",
pages = "670--676",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15

AU - Willson, J. K.V.

AU - Albert, Daniel

AU - Diener-West, M.

AU - McCaffrey, L.

AU - Mo, C. S.

AU - Scully, R. E.

AU - Robinson, N.

AU - Zimbric, M.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: A systematic review and assessment of disease-related mortality as part of standardized prospective patient follow-up and evaluation within a multicenter clinical trial have been lacking in previous studies of choroidal melanoma. Objective: To describe disease status at death in patients with large choroidal melanoma treated and followed up in the Collaborative Ocular Melanoma Study (COMS). Design: Analysis of reviews of patient status at death performed by the COMS Mortality Coding Committee using available clinical and histopathologic information. Setting and Patients: Reviews of deaths as of July 31, 1997, the cutoff date for reporting initial mortality findings. Interventions: Patients were treated by either enucleation preceded by external beam radiotherapy or enucleation only. Main Outcome Measures: Disease status at the time of death and certainty associated with the coding of disease status, sites of metastasis, and availability of autopsy. Results: Of 1003 patients enrolled in the trial, 457 had died; the estimated median survival from time of enrollment was 7.4 years. Disease status at time of death had been reviewed for 435 deaths (95%). The autopsy rate was 6%. A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sties were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis. The likelihood of 3 or more sites increased more than 4-fold when autopsy results were available. Conclusions: Detailed mortality coding following a standard protocol provides the most accurate reporting to date of disease-related mortality in patients with choroidal melanoma and also identifies difficulties. Guidelines for the evaluation of future patients in clinical studies of choroidal melanoma are suggested.

AB - Background: A systematic review and assessment of disease-related mortality as part of standardized prospective patient follow-up and evaluation within a multicenter clinical trial have been lacking in previous studies of choroidal melanoma. Objective: To describe disease status at death in patients with large choroidal melanoma treated and followed up in the Collaborative Ocular Melanoma Study (COMS). Design: Analysis of reviews of patient status at death performed by the COMS Mortality Coding Committee using available clinical and histopathologic information. Setting and Patients: Reviews of deaths as of July 31, 1997, the cutoff date for reporting initial mortality findings. Interventions: Patients were treated by either enucleation preceded by external beam radiotherapy or enucleation only. Main Outcome Measures: Disease status at the time of death and certainty associated with the coding of disease status, sites of metastasis, and availability of autopsy. Results: Of 1003 patients enrolled in the trial, 457 had died; the estimated median survival from time of enrollment was 7.4 years. Disease status at time of death had been reviewed for 435 deaths (95%). The autopsy rate was 6%. A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sties were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis. The likelihood of 3 or more sites increased more than 4-fold when autopsy results were available. Conclusions: Detailed mortality coding following a standard protocol provides the most accurate reporting to date of disease-related mortality in patients with choroidal melanoma and also identifies difficulties. Guidelines for the evaluation of future patients in clinical studies of choroidal melanoma are suggested.

UR - http://www.scopus.com/inward/record.url?scp=0035025251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035025251&partnerID=8YFLogxK

U2 - 10.1001/archopht.119.5.670

DO - 10.1001/archopht.119.5.670

M3 - Article

VL - 119

SP - 670

EP - 676

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 5

ER -